Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene... see more

Recent & Breaking News (OTCPK:TSOI)

Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST

PR Newswire September 7, 2021

Therapeutic Solutions International Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer

PR Newswire August 30, 2021

Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Pioneer Francisco Silva to Scientific Advisory Board

PR Newswire August 26, 2021

Therapeutic Solutions International Announces Positive Preclinical Results Using JadiCells(TM) in Animal Model of Chronic Obstructive Pulmonary Failure (COPD)

PR Newswire August 23, 2021

Therapeutic Solutions International Announces Titan of Industry Dr. Peter Farrell Joins Advisory Board of its Suicide Prevention Spin-Off Campbell Neurosciences

PR Newswire August 20, 2021

Therapeutic Solutions International Recruits Pharmaceutical Industry Veteran Dr. Boris Reznik to Accelerate Value Optimization of FDA Cleared Phase III COVID JadiCell(TM) Clinical Trial

PR Newswire August 19, 2021

Therapeutic Solutions International Identifies and Files Patent on Novel Mechanism of Action of Its FDA Phase III Cleared JadiCell(TM) Treatment of COVID-19 and Delta Variant

PR Newswire August 18, 2021

Therapeutic Solutions International Prepares to Apply for Emergency Use Authorization (EUA) for its FDA Phase III COVID-19 Stem Cell Therapy JadiCell(TM)

PR Newswire August 16, 2021

Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other Stem Cell Types

PR Newswire August 11, 2021

Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell(TM) Chronic Traumatic Encephalopathy (CTE) Clinical Trial

PR Newswire August 9, 2021

Therapeutic Solutions International Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell(TM) Universal Donor COVID-19 Therapy

PR Newswire August 5, 2021

Therapeutic Solutions International Reports Preclinical Efficacy of JadiCell Umbilical Cord Mesenchymal Stem Cells in Animal Model Resembling COVID-19 Delta Variant Associated Lung Pathology

PR Newswire July 27, 2021

Therapeutic Solutions International Spin-Off Campbell Neurosciences Explains Why Suicide is a Disease and How to Predict it in Newly Released Video

PR Newswire July 8, 2021

Therapeutic Solutions International Patents Modified StemVacs Dendritic Cell Immunotherapy to Suppress Parkinson's Disease in Animal Model

PR Newswire July 6, 2021

Therapeutic Solutions International Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score(TM) with California Concierge Medical & Wellness Inc.

PR Newswire July 2, 2021

Therapeutic Solutions International Demonstrates Potent Brain Protective Activity of JadiCells in Animal Model of Post-Covid-19 Neurological Damage

PR Newswire June 30, 2021

Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation

PR Newswire June 16, 2021

Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

PR Newswire June 10, 2021

Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC

PR Newswire June 7, 2021

Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model

PR Newswire June 2, 2021